Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting
Open accessAbstract
OBJECTIVE: To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications. RESEARCH DESIGN AND METHODS: Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR). RESULTS: Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22). ROR was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82–6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs (6 and 4, respectively). CONCLUSIONS: In agreement with preclinical and clinical studies, AERS analysis is consistent with an association between pioglitazone and bladder cancer. This issue needs constant epidemiologic surveillance and urgent definition by more specific studies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is some suggestion of a possible link between pioglitazone and bladder cancer, so individuals with a history of bladder cancer or unexplained hematuria should probably not receive this drug.
“There is also some suggestion of a possible link between pioglitazone and bladder cancer and therefore individuals with a history of bladder cancer or unexplained hematuria should probably not receive this drug.98,99”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596 · see citing works
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works
van Puijenbroek, E., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, T. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,385 · see citing works
Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases
Pariente, A., Grégoire, F., Fourrier‐Réglat, A., Haramburu, F., & Moore, N. D. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00007 · Cited by 270 · see citing works
Perspectives on the Use of Data Mining in Pharmacovigilance
Almenoff, J. S., Tonning, J. M., Gould, A. L., Szarfman, A., Hauben, M., Ouellet‐Hellstrom, R., Ball, R., Hornbuckle, K., Walsh, L., Yee, C., et al. (2005) · Drug Safety · doi:10.2165/00002018-200528110-00002 · Cited by 251 · see citing works
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227 · see citing works
Moore, N., Kreft-Jaïs, C., Haramburu, F., Noblet, C., Andréjak, M., Ollagnier, M., & Bégaud, B. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00615.x · Cited by 134 · see citing works
Antimicrobials and the Risk of Torsades de Pointes
Poluzzi, E., Raschi, E., Motola, D., Moretti, U., & Ponti, F. D. (2010) · Drug Safety · doi:10.2165/11531850-000000000-00000 · Cited by 122 · see citing works
Self-citation???Extreme Duplication??? in the US FDA Adverse Events Reporting System Database
Hauben, M., Reich, L., DeMicco, J., & Kim, K. K. (2007) · Drug Safety · doi:10.2165/00002018-200730060-00009 · Cited by 79 · see citing works
Suzuki, S., Arnold, L. L., Pennington, K. L., Kakiuchi-Kiyota, S., Wei, M., Wanibuchi, H., & Cohen, S. M. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp256 · Cited by 78 · see citing works
Glucocorticoid therapy and risk of bladder cancer
Dietrich, K., Schned, A. R., Fortuny, J., Heaney, J., Marsit, C. J., Kelsey, K. T., & Karagas, M. R. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605314 · Cited by 65 · see citing works
Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003–2009
Cohen, A. J., Rabbani, A., Shah, N. D., & Alexander, G. C. (2010) · Diabetes Care · doi:10.2337/dc09-1834 · Cited by 51 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958 · see citing works
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,071 · see citing works
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806 · see citing works
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · see citing works
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · see citing works
Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 518 · see citing works
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518 · see citing works
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3214 · Cited by 494 · see citing works
Case-non-case studies: principle, methods, bias and interpretation
Faillie, J.-L. (2019) · Therapies · doi:10.1016/j.therap.2019.01.006 · Cited by 336 · see citing works
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 288 · see citing works
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 270 · see citing works
Azoulay, L., Yin, H., Filion, K. B., Assayag, J., Majdan, A. A., Pollak, M., & Suissa, S. (2012) · BMJ · doi:10.1136/bmj.e3645 · Cited by 267 · see citing works
Nathan, D. M., Buse, J. B., Kahn, S. E., Krause-Steinrauf, H. J., Larkin, M., Staten, M. A., Wexler, D. J., & Lachin, J. M. (2013) · Diabetes Care · doi:10.2337/dc13-0356 · Cited by 255 · see citing works
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
Shlomai, G., Neel, B. A., LeRoith, D., & Gallagher, E. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4044 · Cited by 237 · see citing works
Poluzzi, E., Raschi, E., Piccinni, C. P., & De, F. (2012) · InTech eBooks · doi:10.5772/50095 · Cited by 227 · see citing works
Self-citationCritical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Rosak, C., & Mertes (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s28340 · Cited by 221 · see citing works
Insulin Resistance and Cancer: In Search for a Causal Link
CHIEFARI, E. D., Mirabelli, M., Vignera, S. L., Tanyolaç, S., FOTI, D. P., Aversa, A., & Brunetti, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011137 · Cited by 175 · see citing works
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-014-3456-9 · Cited by 158 · see citing works
Colmers-Gray, I. N., Bowker, S. L., Majumdar, S. R., & Johnson, J. A. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.112102 · Cited by 156 · see citing works
Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies
Ferwana, M. S., Firwana, B., Hasan, R., Al-Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H. (2013) · Diabetic Medicine · doi:10.1111/dme.12144 · Cited by 147 · see citing works
Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
Bosetti, C., Rosato, V., Buniato, D., Zambon, A., Vecchia, C. L., & Corrao, G. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0302 · Cited by 144 · see citing works
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
Turner, R. M., Kwok, C. S., Chen‐Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12306 · Cited by 126 · see citing works
Raschi, E., Piccinni, C. P., Poluzzi, E., Marchesini, G., & Ponti, F. D. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0340-7 · Cited by 126 · see citing works
Self-citationPioglitazone and Bladder Cancer
Tseng, C.-H. (2012) · Diabetes Care · doi:10.2337/dc11-1449 · Cited by 123 · see citing works
Raschi, E., Poluzzi, E., Salvo, F., Pariente, A., De Ponti, F., Marchesini, G., & Moretti, U. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.02.014 · Cited by 119 · see citing works
Self-citationThiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
Monami, M., Dicembrini, I., & Mannucci, E. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0504-8 · Cited by 115 · see citing works
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 114 · see citing works
Anagnostis, P. G., Katsiki, N., Adamidou, F., Athyros, V. G., Karagiannis, A. I., Kita, M. D., & Mikhailidis, D. P. (2012) · Metabolism · doi:10.1016/j.metabol.2012.05.002 · Cited by 107 · see citing works
Non-alcoholic fatty liver disease: a practical approach to treatment
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100404 · Cited by 107 · see citing works
Zhu, Z., Wang, X., Shen, Z., Lu, Y., Zhong, S., & Chen, X. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-310 · Cited by 93 · see citing works
Esther Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 91 · see citing works
Latest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 88 · see citing works
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Filipova, E. P., Uzunova, K. H., Kalinov, K., & Vekov, T. Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 88 · see citing works
Zhang, F., Kong, D., Lu, Y., & Zheng, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1046-x · Cited by 87 · see citing works
Data Mining Applications in Engineering and Medicine
Adem Karahoca, A. (2012) · InTech eBooks · doi:10.5772/2616 · Cited by 85 · see citing works
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Cancer Science · doi:10.1111/cas.12203 · Cited by 82 · see citing works
History of current non-insulin medications for diabetes mellitus
Quianzon, C. C. L., & Cheikh, I. E. (2012) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v2i3.19081 · Cited by 82 · see citing works
Gandhi, P., Gentry, W. M., & Bottorff, M. B. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01126 · Cited by 77 · see citing works
Non-alcoholic fatty liver disease in 2016
Townsend, S. A., & Newsome, P. N. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw031 · Cited by 73 · see citing works
Punicic acid: A potential compound of pomegranate seed oil in Type 2 diabetes mellitus management
Khajebishak, Y., Payahoo, L., Alivand, M. R., & Alipour, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27556 · Cited by 73 · see citing works
Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies
Zhu, Z., Zhang, X., Shen, Z., Zhong, S., Wang, X., Lu, Y., & Chen, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056662 · Cited by 72 · see citing works
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 70 · see citing works
Hsiao, F., Hsieh, P.-H., Huang, W.-F., Tsai, Y., & Gau, C. (2013) · Drug Safety · doi:10.1007/s40264-013-0080-4 · Cited by 69 · see citing works
Rosenson, R. S., Wright, R. S., Farkouh, M. E., & Plutzky, J. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.06.023 · Cited by 67 · see citing works
Review article: new treatments in non‐alcoholic fatty liver disease
Townsend, S. A., & Newsome, P. N. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14210 · Cited by 66 · see citing works
New lipid-lowering drugs: an update
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02867.x · Cited by 65 · see citing works
Choi, C. (2019) · Marine Drugs · doi:10.3390/md17040242 · Cited by 64 · see citing works
Zhu, Z., Shen, Z., Lu, Y., Zhong, S., & Chen, X. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.006 · Cited by 62 · see citing works
Les études cas–non cas : principe, méthodes, biais et interprétations
Faillie, J. (2017) · Therapies · doi:10.1016/j.therap.2017.08.006 · Cited by 59 · see citing works
PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells
Cheng, S., Qian, K., Wang, Y., Wang, G., Liu, X., Xiao, Y., & Wang, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14280 · Cited by 53 · see citing works
Pioglitazone and bladder cancer
Hillaire‐Buys, D., Faillie, J., & Montastruc, J. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61662-0 · Cited by 53 · see citing works
Smith, R. C., Jin, H., Li, C., Bark, N. M., Shekhar, A., Dwivedi, S., Mortiere, C., Lohr, J. B., Hu, Q., & Davis, J. M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.023 · Cited by 52 · see citing works
Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets
Maciejewski, M., Lounkine, E., Whitebread, S., Farmer, P. J., DuMouchel, W., Shoichet, B. K., & Urbán, L. (2017) · eLife · doi:10.7554/elife.25818 · Cited by 46 · see citing works
Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators
Corigliano, D. M., Syed, R., Messineo, S., Lupia, A., Patel, R. V., Reddy, C. V. R., Dubey, P. K., Colica, C., Amato, R., Sarro, G. D., et al. (2018) · PeerJ · doi:10.7717/peerj.5386 · Cited by 49 · see citing works
Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety
Raschi, E., Moretti, U., Salvo, F., Pariente, A., Antonazzo, I. C., Ponti, F. D., & Poluzzi, E. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79986 · Cited by 48 · see citing works
Self-citationDu, Q., Yang, S., Wang, Y.-J., Wu, B., Zhao, Y.-Y., & Fan, B. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0044-6 · Cited by 47 · see citing works
Raschi, E., Parisotto, M., Forcesi, E., Plaça, M. L., Marchesini, G., Ponti, F. D., & Poluzzi, E. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.008 · Cited by 47 · see citing works
Self-citationHe, S., Tang, Y.-H., Zhao, G., Yang, X., Wang, D., & Zhang, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1278-x · Cited by 44 · see citing works
Treatment of Non-Alcoholic Fatty Liver Disease
Dyson, J. K., & Day, C. (2014) · Digestive Diseases · doi:10.1159/000360511 · Cited by 43 · see citing works
Lin, H. C., Hsu, Y.-T., Kachingwe, B., Hsu, C.-Y., Uang, Y., & Wang, L.-H. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12151 · Cited by 40 · see citing works
A Review on Thiazolidinediones and Bladder Cancer in Human Studies
Tseng, C. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.877645 · Cited by 41 · see citing works
Pioglitazone in Clinical Practice: Where Are We Now?
Govindan, J., & Evans, M. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0001-z · Cited by 40 · see citing works
Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 42 · see citing works
Kehinde, E. O. (2013) · Medical Principles and Practice · doi:10.1159/000355504 · Cited by 39 · see citing works
Tseng, C. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2011.10.003 · Cited by 38 · see citing works
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit
Ryder, R. E. J. (2014) · Diabetic Medicine · doi:10.1111/dme.12627 · Cited by 37 · see citing works
Report of the JDS/JCA Joint Committee on Diabetes and Cancer
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0121-3 · Cited by 37 · see citing works
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones
Motola, D., Piccinni, C. P., Biagi, C., Raschi, E., Marra, A. R., Marchesini, G., & Poluzzi, E. (2012) · Drug Safety · doi:10.2165/11596510-000000000-00000 · Cited by 37 · see citing works
Self-citationKanai, S., Ishihara, K., Kawashita, E., Tomoo, T., Nagahira, K., Hayashi, Y., & Akiba, S. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229906 · Cited by 37 · see citing works
Yan, H., Xie, H., Ying, Y., Li, J., Wang, X., Xu, X., & Zheng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s164840 · Cited by 36 · see citing works
Yue, Z., Shi, J., Jiang, P., & Sun, H. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3626 · Cited by 35 · see citing works
The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
Song, S. O., Kim, K. J., Lee, B., Kang, E. S., Soo, B., & Lee, H. C. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.371 · Cited by 35 · see citing works
Challenges in drug discovery for thiazolidinedione substitute
Ye, J. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.06.011 · Cited by 35 · see citing works
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes
Fujimoto, K., Hamamoto, Y., Honjo, S., Kawasaki, Y., Mori, K., Tatsuoka, H., Matsuoka, A., Wada, Y., Ikeda, H., Fujikawa, J., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.013 · Cited by 34 · see citing works
Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus
Blonde, L., Juan, Z. T. S., & Bolton, P. (2014) · Endocrine Practice · doi:10.4158/ep14259.ra · Cited by 34 · see citing works
Mehtälä, J., Khanfir, H., Bennett, D., Ye, Y., Korhonen, P. A., & Hoti, F. J. (2018) · Diabetology International · doi:10.1007/s13340-018-0360-4 · Cited by 34 · see citing works
Pioglitazone use and the risk of bladder cancer
Kuo, H., Tiao, M., Ho, S., & Yang, C. (2013) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2013.09.011 · Cited by 33 · see citing works
Yoon, K., Steinberg, H. O., Teng, R., Golm, G. T., Lee, M. M.-S., O’Neill, E. A., Kaufman, K. D., & Goldstein, B. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01594.x · Cited by 33 · see citing works
Yue, Z., Jiang, P., Sun, H., & Wu, J. H. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1643-8 · Cited by 33 · see citing works
Raschi, E., Poluzzi, E., Koci, A., Antonazzo, I. C., Marchesini, G., & Ponti, F. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.006 · Cited by 33 · see citing works
Self-citationPrevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 35 · see citing works
Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma
Yang, C. Z., Hou, K., Wang, Y., Chen, Y., Zheng, X., Qi, J., Yang, B., Tang, S., Han, X., Shi, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665276 · Cited by 33 · see citing works
Mao, S., Xiaoli, Z., Zhang, B., Wang, R., & Lin, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147048 · Cited by 32 · see citing works
Terrasi, M., Bazan, V., Caruso, S., Insalaco, L., Amodeo, V., Fanale, D., Corsini, L. R., Contaldo, C., Mercanti, A., Fiorio, E., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24295 · Cited by 31 · see citing works
Kao, C., Sun, L. M., Chen, P., Lin, M.-C., Liang, J., Muo, C.-H., Chang, S.-N., & Sung, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds472 · Cited by 30 · see citing works
Does long-term use of antidiabetic drugs changes cancer risk?
Liu, Y.-C., Nguyen, P.-A., Humayun, A., Chien, S.-C., Yang, H., Asdary, R. N., Syed-Abdul, S., Hsu, M., Moldovan, M. V., Yen, Y., et al. (2019) · Medicine · doi:10.1097/md.0000000000017461 · Cited by 30 · see citing works
Lee, M., Hsiao, P., Yang, Y., Lin, K., & Shin, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085479 · Cited by 29 · see citing works
Metabolic syndrome in the Mediterranean region: Current status
Anagnostis, P. G. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.91195 · Cited by 28 · see citing works
Alba, M., Åhrén, B., Inzucchi, S. E., Guan, Y., Mallick, M., Xu, L., O’Neill, E. A., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12145 · Cited by 27 · see citing works
Faillie, J., Petit, P., Montastruc, J., & Hillaire‐Buys, D. (2013) · Drug Safety · doi:10.1007/s40264-013-0086-y · Cited by 27 · see citing works
Rajagopalan, S., Dutta, P. R., Hota, D., Bhansali, A. K., Srinivasan, A., & Chakrabarti, A. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.030 · Cited by 27 · see citing works
Antonazzo, I. C., Poluzzi, E., Forcesi, E., Salvo, F., Pariente, A., Marchesini, G., Ponti, F. D., & Raschi, E. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01378-7 · Cited by 27 · see citing works
Self-citationVascular Complications of Diabetes Mellitus
Chiong, Y., & Evans‐Molina, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_49 · Cited by 27 · see citing works
Update on Safety Issues Related to Antihyperglycemic Therapy
Carpio, G., & Fonseca, V. A. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.92 · Cited by 27 · see citing works
Pioglitazone: Indian perspective
Shukla, R., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85581 · Cited by 26 · see citing works
Garry, E. M., Buse, J. B., Lund, J. L., Pate, V., & Stürmer, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13049 · Cited by 25 · see citing works
Raschi, E., Mazzotti, A., Poluzzi, E., Ponti, F. D., & Marchesini, G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1531126 · Cited by 24 · see citing works
Self-citationIntervention of Prediabetes by Flavonoids From Oroxylum indicum
Dong, Y., Zhang, B., Sun, W., & Xing, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813822-9.00036-9 · Cited by 23 · see citing works
Pioglitazone – Do we really need it to manage type 2 diabetes?
Sinha, B., & Ghosal, S. (2013) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.06.005 · Cited by 22 · see citing works
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
Dejager, S., Schweizer, A., & Foley, J. E. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s31758 · Cited by 21 · see citing works
- Authors
- Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Poluzzi, Elisabetta
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-05-20
- Volume
- 34
- Issue
- 6
- Pages
- 1369-1371
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3114317
- OpenAlex
- W2133104620
- Cited by
- 239
- References
- 12
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 14 · 2015: 20 · 2014: 23 · 2013: 37 · 2012: 60
- FWCI
- 56.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pioglitazone, bladder cancer, drug adverse events, antidiabetic drugs, FDA Adverse Event Reporting System, reporting odds ratio, insulin, metformin, glimepiride, exenatide, gliclazide, acarbose, drug safety
- MeSH terms
- Pioglitazone, Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, United States, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
